GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
St. Jude Medical, Inc. (STJ) [hlAlert]

Rating:
Outperform
STJ
up 77.91 %

St. Jude Medical, Inc. (STJ) rated Outperform by BMO Capital Markets

Posted on: Monday,  Jan 7, 2008  9:25 AM ET by BMO Capital Markets

BMO Capital Markets rated Outperform St. Jude Medical, Inc. (NYSE: STJ) on 01/07/2008, when the stock price was $40.71.
Since then, St. Jude Medical, Inc. has gained 77.92% as of 01/28/2016's recent price of $72.43.
If you would have followed this BMO Capital Markets's recommendation on STJ, you would have gained 77.91% of your investment in 2943 days.

St. Jude Medical, Inc. (St. Jude)develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. The Company operates in four business segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation Systems (Neuro). On July 3, 2008, the Company completed the acquisition of EP MedSystems, Inc. On December 19, 2008, St. Jude acquired Radi Medical Systems. On December 22, 2008, St. Jude acquired MediGuide Inc.

The U.S. Equity Research team comprises over 25 analysts located in New York, Atlanta, Boston, Denver, Houston and Los Angeles. We cover more than 375 stocks and also provide equity strategy, quantitative analysis and portfolio management services to our clients. Our goal is to identify the best sectors to invest in, and the best stocks within those sectors, in order to help our clients maximize their portfolio returns. Our award-winning analysts provide research that is informative, perceptive and actionable.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/7/2008 9:25 AM Buy
None
40.71
as of 12/24/2008
1 Week down  -4.08 %
1 Month down  -8.07 %
3 Months up  11.92 %
1 YTD down  -16.03 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy